Peddling Prescription Plans

Stone, Peter H.
July 2002
National Journal;7/13/2002, Vol. 34 Issue 28, p2072
Focuses on issues related to a proposed Medicare prescription drug benefit in the U.S. as of July 2002. Information on a meeting held by the Pharmaceutical Research and Manufacturers of America for political plans and priorities; Criticisms against the U.S. drug industry; Legislation on prescription drug medications.


Related Articles

  • State lawmakers wrestling with Rx costs and access. Conlan, Michael F. // Drug Topics;5/1/2000, Vol. 144 Issue 9, p70 

    Deals with the move of state legislatures in the United States (US) to enact bills to impose price controls on medicine prescriptions (Rx). Impact on drug manufacturers and dealers; Actions taken by several US states on dispensing of Rx costs.

  • PhRMA challenges Maine's novel Rx law. Tieman, Jeff // Modern Healthcare;08/14/2000, Vol. 30 Issue 34, p12 

    Focuses on the legal challenges filed by the Pharmaceutical Research and Manufacturers of America (PhRMA) against the Maine Rx Program, a law that will control prescription drug prices. Goal of the Maine Rx Program; Remarks from Chellie Pingree, Democratic majority leader in the Maine Senate, on...

  • Did AARP Sell Out Seniors? Florian, Ellen; Novelli, Bill // Fortune;12/8/2003, Vol. 148 Issue 12, p48 

    Presents an interview with AARP CEO Bill Novelli regarding the $400 billion Republican-led Medicare prescription-drug bill now headed for a vote in Congress. Endorsement of the bill by AARP in spite of calling it "far from perfect;" Opposition from Senator Ted Kennedy, Democrats and members of AARP.

  • No: Letting Washington set prices will hurt seniors and stifle research and development. Holmer, Alan F. // Insight on the News;06/14/99, Vol. 15 Issue 22, p25 

    Asserts that the United States government should develop a prescription-drug program that supports innovation and gives senior citizens more choices. Flaws of the House Resolution 664 proposed by Representative Tom Allen; Accomplishments of pharmaceutical research; Cost of medical innovation;...

  • Mass. debates Rx coupons. DeArment, Alaric // Drug Store News;5/17/2010, Vol. 32 Issue 6, p70 

    The article reports on the introduction of the prescription discount bill by members of Massachusetts' state House whicch would wash away the old law that keeps drug companies from competing against health insurers banning the use of drug coupons.

  • Advisory pricing panel still alive in Congress.  // Drug Topics;6/27/94, Vol. 138 Issue 12, p5 

    Reports on the intention of two of the three House Committees working on health care reform legislation to include some kind of advisory council on prices of prescribed drugs as part of the final package. House Education and Labor Committee; House Ways and Means Committee; Study on the...

  • Health reform has new drug sales fee. J. G. D. // Medical Marketing & Media;May2010, Vol. 45 Issue 5, p32 

    The article reports on the annual fee on brand-name prescription drug manufacturers and importers provided by the healthcare reform in the U.S.

  • Prescription Drug Coverage for Senior Citizens Mulled.  // Chemical Market Reporter;06/14/99, Vol. 255 Issue 24, p69 

    Provides information on a legislation introduced in the United States which addressed prescription drug coverage for senior citizens in the country. Provisions of the bill; Support of the pharmaceutical industry for the legislation; Sponsor of the bill.

  • PBMs play integral role in cost, quality control. Wechsle, Jill // Managed Healthcare Executive;Feb2003, Vol. 13 Issue 2, p8 

    Focuses on the role of pharmacy benefit managers (PBM) in providing pharmacy programs in the U.S. Increase in demand for inpatient care; Development of Medicare drug benefit; Reduction of drug costs by PBM.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics